NEWS: Ground-breaking new Jenner Institute Malaria Vaccine 77% effective in early trials

Lion's Head Global Partners is proud to be supporting the Serum Institute of India Pvt. Ltd. for their Phase 3 pivotal trial of R21, a new vaccine developed against plasmodium falciparum by the Jenner Institute, Oxford. This vaccine showed a 77% efficacy in its Phase 2 trial and is the first malaria vaccine to meet the WHO goal of 75% efficacy against this disease. The Phase 3 trial is now commencing across 5 sites in Africa in Burkina Faso, Gabon, Kenya and Mali, with an enrolment target of 4,800. If the Phase 2 results are repeated this will enable registration of this vaccine in 2022. Around 400,000 people die every year from malaria globally, more than 90% of them in sub-Saharan Africa, of which 250,000 were under the age of 5 (7% of all childhood deaths globally).

Written by
Christopher Egerton-Warburton
Published on